merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Skepticism surrounds Kisunla's approval due to the lack of a noticeable benefit to patients and families, and the significant safety risks, including brain swelling and bleeding.</answer>
<question_number>2</question_number>
<answer>The focus on anti-amyloid drugs might discourage patients from participating in trials for potentially better treatments, slowing progress in the field.</answer>
<question_number>3</question_number>
<answer>According to Dr. Greicius, there is no correlation in any of the studies between the removal of amyloid plaques and the clinical response in individual subjects.</answer>
<question_number>4</question_number>
<answer>The higher rates of swelling and bleeding in the donanemab trial compared to the Leqembi trial may raise concerns about Kisunla's safety, potentially affecting its perception negatively.</answer>
<question_number>5</question_number>
<answer>The cost of Kisunla might be justified by the expectation that patients can stop the drug after their amyloid plaques are cleared, reducing overall treatment duration and cost.</answer>
<question_number>6</question_number>
<answer>The article suggests that the emphasis on anti-amyloid drugs might discourage patients from participating in trials for other treatments that could be better.</answer>
<question_number>7</question_number>
<answer>The article explains that Kisunla can reduce the inconvenience of treatment by allowing patients to stop the drug after amyloid plaques are cleared, unlike Leqembi, which is given continuously.</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels, suggesting that treating patients earlier in the disease progression might be more effective.</answer>